Trial Profile
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary)
- Indications Pulmonary embolism
- Focus Diagnostic use
- 25 Jul 2022 Status changed from recruiting to completed.
- 27 May 2021 Planned End Date changed from 31 May 2021 to 31 May 2023.
- 27 May 2021 Planned primary completion date changed from 31 May 2020 to 31 May 2022.